57 related articles for article (PubMed ID: 16330454)
1. The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma.
Fields PA; Mikhaeel G; Hutchings M; van der Walt J; Nunan T; Schey SA
Haematologica; 2005 Dec; 90(12):1711-3. PubMed ID: 16330454
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
[TBL] [Abstract][Full Text] [Related]
3. Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Anderson H; Dictor M; Kvaløy S; Akerman M; Cavallin-Ståhl E;
Ann Hematol; 2004 Jul; 83(7):414-9. PubMed ID: 15085385
[TBL] [Abstract][Full Text] [Related]
4. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.
de Jong D; Rosenwald A; Chhanabhai M; Gaulard P; Klapper W; Lee A; Sander B; Thorns C; Campo E; Molina T; Norton A; Hagenbeek A; Horning S; Lister A; Raemaekers J; Gascoyne RD; Salles G; Weller E;
J Clin Oncol; 2007 Mar; 25(7):805-12. PubMed ID: 17327602
[TBL] [Abstract][Full Text] [Related]
6. Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
Vitolo U; Botto B; Capello D; Vivenza D; Zagonel V; Gloghini A; Novero D; Parvis G; Calvi R; Ariatti C; Milan I; Bertini M; Boccomini C; Freilone R; Pregno P; Orsucci L; Palestro G; Saglio G; Carbone A; Gallo E; Gaidano G
Leukemia; 2002 Feb; 16(2):268-75. PubMed ID: 11840294
[TBL] [Abstract][Full Text] [Related]
7. Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma.
Hüttmann A; Müller S; Jöckel KH; Dührsen U
J Clin Oncol; 2010 Sep; 28(27):e488-9; author reply e490-1. PubMed ID: 20644097
[No Abstract] [Full Text] [Related]
8. Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: qualitative or quantitative interpretation--where do we stand?
Meignan M; Itti E; Gallamini A; Haioun C
Leuk Lymphoma; 2009 Nov; 50(11):1753-6. PubMed ID: 19863178
[TBL] [Abstract][Full Text] [Related]
9. [Value of interim 18F-FDG PET-CT examination in evaluation of chemotherapy response and prognosis in patients with diffuse large B-cell lymphoma].
Ding C; Li T; Fan L; Xu W; Li J; Sun J; Ding Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):342-4. PubMed ID: 24759025
[No Abstract] [Full Text] [Related]
10. Prognostic impact of pre-transplantation computed tomography and 67gallium scanning in chemosensitive diffuse large B cell lymphoma patients undergoing hematopoietic stem-cell transplantation.
Escobar IG; Alonso PT; Barrigon DC; Perez-Simon JA; Mateos Manteca MV; San Miguel Izquierdo JF
Ann Nucl Med; 2008 May; 22(4):251-60. PubMed ID: 18535875
[TBL] [Abstract][Full Text] [Related]
11. Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons.
Hutchison RE; Finch C; Kepner J; Fuller C; Bowman P; Link M; Schwenn M; Laver J; Desai S; Barrett D; Murphy SB
Ann Oncol; 2000; 11 Suppl 1():35-8. PubMed ID: 10707776
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.
Nyman H; Jerkeman M; Karjalainen-Lindsberg ML; Banham AH; Enblad G; Leppä S
Eur J Haematol; 2009 May; 82(5):364-72. PubMed ID: 19141121
[TBL] [Abstract][Full Text] [Related]
14. The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma.
Hoppe BS; Moskowitz CH; Zhang Z; Maragulia JC; Rice RD; Reiner AS; Hamlin PA; Zelenetz AD; Yahalom J
Bone Marrow Transplant; 2009 Jun; 43(12):941-8. PubMed ID: 19139730
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
Kostakoglu L; Goldsmith SJ; Leonard JP; Christos P; Furman RR; Atasever T; Chandramouly A; Verma S; Kothari P; Coleman M
Cancer; 2006 Dec; 107(11):2678-87. PubMed ID: 17063502
[TBL] [Abstract][Full Text] [Related]
16. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2.
Xu Y; McKenna RW; Molberg KH; Kroft SH
Am J Clin Pathol; 2001 Aug; 116(2):183-90. PubMed ID: 11488064
[TBL] [Abstract][Full Text] [Related]
18. Both Interim and End-of-Treatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography Scans Have Low Value in Diffuse Large B-Cell Lymphoma.
Adams HJ; Kwee TC
J Clin Oncol; 2016 Mar; 34(7):765-6. PubMed ID: 26755517
[No Abstract] [Full Text] [Related]
19. Mixed response in interim positron emission tomography/computed tomography leads to detection of a gastrointestinal stromal tumor in a patient with mediastinal diffuse large B-cell lymphoma.
Rehmsmeier C; Kessler T; Koschmieder S; Ross M; Weckesser M; Wessling J; Koehler G; Berdel WE
J Clin Oncol; 2010 May; 28(14):e215-7. PubMed ID: 20194849
[No Abstract] [Full Text] [Related]
20. Diffuse large B cell lymphoma with chronic granulomatous inflammation.
Nyunt WW; Wong YP; Wan Jamaludin WF; Abdul Wahid SF
Malays J Pathol; 2016 Apr; 38(1):55-9. PubMed ID: 27126666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
